{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
bioAffinity Technologies, Inc.
bioAffinity Technologies Hits New 52-Week Low at $2.05
bioAffinity Technologies, Inc. has reached a new 52-week low, reflecting ongoing struggles in the Pharmaceuticals & Biotechnology sector. The company has faced a decline in performance, negative operating cash flow, and weak sales, highlighting significant challenges in its financial health and market position.
bioAffinity Technologies Hits 52-Week Low at $2.27 Amidst 94% Decline
bioAffinity Technologies, Inc. has reached a new 52-week low, reflecting ongoing challenges in the competitive Pharmaceuticals & Biotechnology sector. With a market cap of USD 7 million, the company faces significant financial hurdles, including an operating loss, negative cash flow, and a stark decline in stock performance over the past year.
bioAffinity Technologies, Inc. Hits New 52-Week High of $5.24
bioAffinity Technologies, Inc. has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. The company, operating in the Pharmaceuticals & Biotechnology sector, has shown strong financial metrics despite being loss-making, highlighting its potential within the microcap market.
bioAffinity Technologies Hits New 52-Week High of $5.23, Marking Major Milestone
bioAffinity Technologies, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. With a market capitalization of USD 7 million, the company demonstrates strong efficiency in generating profits, despite being loss-making. Its low debt-to-equity ratio indicates a conservative financial strategy in a competitive industry.
Is bioAffinity Technologies, Inc. technically bullish or bearish?
As of August 14, 2025, bioAffinity Technologies, Inc. has shifted to a mildly bearish trend, with mixed indicators showing bearish signals from Bollinger Bands and moving averages, while the On-Balance Volume remains bullish, and the stock has significantly underperformed the S&P 500 year-to-date.
Is bioAffinity Technologies, Inc. overvalued or undervalued?
As of February 9, 2024, bioAffinity Technologies, Inc. is rated as risky due to overvaluation and poor financial metrics, including a Price to Book Value of 5.62 and negative returns on capital and equity, significantly underperforming its peers and the S&P 500 with a year-to-date return of -81.42%.
Is bioAffinity Technologies, Inc. overvalued or undervalued?
As of February 9, 2024, bioAffinity Technologies, Inc. is rated "risky" and considered overvalued due to negative financial metrics, including a Price to Book Value of 5.62 and significantly negative ROCE and ROE, while underperforming against peers and the S&P 500 with a year-to-date decline of 74.7%.
Is bioAffinity Technologies, Inc. technically bullish or bearish?
As of May 12, 2025, the technical trend is mildly bearish, indicated by mixed signals from MACD, RSI, Bollinger Bands, and moving averages, reflecting a lack of strength in the bullish direction.
What does bioAffinity Technologies, Inc. do?
bioAffinity Technologies, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $2 million and a net loss of $3 million as of March 2025, with a market cap of $7.65 million. Key metrics include a debt-to-equity ratio of 0.17 and a return on equity of -676.56%.
How big is bioAffinity Technologies, Inc.?
As of Jun 18, bioAffinity Technologies, Inc. has a market capitalization of 7.65 million, with net sales of 8.81 million and a net profit of -9.74 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
